Artificial Coma/Medically Induced Coma Market Size (2024 - 2029)

Artificial Coma/Medically Induced Coma Market Analysis

The Artificial Coma/Medically Induced Coma Market is expected to register a CAGR of 3% during the forecast period.

Factors such as an increase in cases of brain injury and diseases and a rise in surgical procedures, coupled with the increased adoption of artificial coma to protect the brain during significant neurosurgery, are expected to bolster the market growth over the study period. Furthermore, the rising prevalence of neurological diseases globally is anticipated to boost the market growth over the forecast period. For instance, according to a study published in the Journal of Clinical Medicine in February 2023, neurological disorders currently affect around 15% of the global population. They are among the leading causes of physical and cognitive disabilities worldwide.

Furthermore, according to the American Cancer Society 2023 update, about 24,810 cases of new malignant tumors of the brain or spinal cord cases were diagnosed in 2023 in the United States. These numbers would be much higher if benign (non-cancer) tumors were also included. Therefore, the high estimated prevalence of neurological cancers is anticipated to increase the demand for artificial coma, bolstering the market growth.

Moreover, a rise in the adoption of artificial coma drugs in major brain surgeries may further contribute to market growth. For instance, according to an article published in PubMed in January 2022, propofol causes a specific reorganization of the brain's neural networks when a person loses consciousness. The brain network's response to propofol in individuals with consciousness problems may disclose the patient's underlying potential for consciousness.

Furthermore, the presence of key players and their strategic product launches are expected to bolster market growth. For instance, in August 2022, Genixus, a pharmaceutical company, launched propofol as a critical offering in its KinetiX platform, specifically in RTA syringe products. The KinetiX RTA platform debuted its propofol syringe, which was designed to optimize workflows and improve care delivery.

Thus, the high prevalence of brain-related diseases and the rise in the adoption of artificial coma procedures are expected to bolster market growth. However, the side effects, such as confusion, delirium, and immobility, associated with artificial coma may hinder the market growth over the forecast period.

Artificial Coma/Medically Induced Coma Industry Segmentation

As per the scope of the report, a controlled amount of an anesthetic agent, such as barbiturates like pentobarbital or thiopental, causes a transient coma known as an induced coma, sometimes referred to as a medically induced coma, barbiturate-induced coma, or drug-induced coma.

The artificial coma/medically induced coma market is segmented by drug type, application, distribution channel, and geography. By drug type, the market is segmented into propofol, barbiturate, and other drug types. By application, the market is segmented into status epilepticus, stroke, traumatic brain injury, brain infections, drug overdose, and other applications. By distribution channel, the market is segmented into hospital pharmacies, drug stores, and retail pharmacies. By geography, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the world. The report offers the market sizes and forecasts in terms of value (USD) for all the abovementioned segments.